Arbogast Pharmaceuticals, Inc. was founded in 1997 to develop diagnostics and therapeutics around the TxPA Technology. The company is incorporated in the State of Tennessee. Dr. Bradley Arbogast acquired patent #4,699,878 from East Tennessee State University in 1995 and filed for an improved method to measure TxPA in 2000. International patents for the improved TxPA assay were filed in 2001. In 2002, Arbogast Pharmaceuticals, Inc. filed a provisional patent for a therapeutic drug to elevate TxPA levels in humans.

Arbogast Pharmaceuticals was granted a Phase I SBIR Grant in September of 2001 to develop the current diagnostic test to identify individuals in the general population who are most at risk to develop any of a number of diseases including heart disease, stroke, cancer and preeclampsia.

Arbogast Pharmaceuticals is currently developing a drug therapy that will delay the onset of a host of fatal diseases associated with aging. By delaying the onset and progression of cardiovascular disease, cancer and stroke, the therapeutic effects of this drug may extend lifespan by as much as 30 years.